Pneumococcal conjugate vaccine is immunogenic in lung fluid of HIV-infected and immunocompetent adults

Gordon, Stephen B.; Käyhty, Helena; Molyneux, Malcolm E.; Haikala, Raili; Nurkka, Anu; Musaya, Janelisa; Zijlstra, Eduard E.; Lindell, Dennis M.; French, Neil

doi:10.1016/j.jaci.2007.03.050

Cited by 18 publications

(9 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The specific IgG response to pneumococcal vaccine in bronchoalveolar lavage fluid and serum was measured in 19 HIV-infected subjects with normal CD4 1 T cells and in 22 HIV-negative subjects. 74 All immunized subjects showed adequate specific response to the 4 serotypes tested in both fluids, which confirms previous findings and supports the observed reductions in pneumococcal disease in this population. Fletcher et al 75 presented pediatric pharmacokinetic data of a fusion protein bearing the CD4 molecule and the immunoglobulin molecule IgG2.…”

Section: Hiv Infectionsupporting

confidence: 91%

Advances in basic and clinical immunology in 2007

Chinen

Shearer

2008

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

Section: Hiv Infectionsupporting

confidence: 91%

Advances in basic and clinical immunology in 2007

Chinen

Shearer

2008

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

“…Immunological parameters currently utilized in immunogenicity studies exclude any potential impact of PCV on mucosal defenses that could contribute to colonization and protective immunity. Increases in serotype-specific IgG or IgA concentrations have been detected in the lung fluid of HIV+ subjects and saliva of immunocompetent adults following conjugate vaccination [42,43]. Presently, mucosal antibody levels and nasopharyngeal colonization are not routinely measured in immunogenicity studies or efficacy trials, but should be considered as possible measures of protection in addition to ELISA and OPA assays.…”

Section: Discussionmentioning

confidence: 99%

Quantitative and Functional Antibody Responses to the 13-Valent Conjugate and/or 23-Valent Purified Polysaccharide Vaccine in Aging HIV-Infected Adults

et al. 2016

View full text Add to dashboard Cite

Background The number of aging human immunodeficiency virus-infected (HIV+) individuals living in the United States has substantially grown over the past two decades. Advanced age and HIV infection both increase susceptibility to Streptococcus pneumoniae infection due to B cell dysfunction. The combined impact of these factors on pneumococcal vaccine responses remains unknown. Methods We assessed serum immunoglobulin (Ig) G and IgM levels and opsonophagocytic killing assay (OPA) titers to pneumococcal serotypes 14 and 23F in HIV+ subjects and HIV-uninfected (HIV−) controls 50–65 years old. HIV+ individuals with CD4+ T cells/μl (CD4) >200 and ≥1 year of antiretroviral therapy (ART) received either a dose of the 13-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine 8 weeks later (PCV/PPV) as currently recommended (n=15) or a single dose of PPV only (n=22). HIV− controls received PCV/PPV (n=14). Results HIV+ PCV/PPV and PPV groups exhibited similar increases in IgG levels and OPA titers for both serotypes after immunization. Postvaccination IgM levels for serotype 23F, but not 14, were significantly higher in HIV+ PCV/PPV compared to PPV groups. IgG and IgM levels for serotype 14 and OPA titers to serotype 23F were significantly reduced in HIV+ compared to HIV− PCV/PPV groups. Serotype-specific IgG levels correlated with OPA titers for all groups. Conclusions Our data suggest that the recommended PCV/PPV regimen may not significantly improve quantitative or functional antibody responses compared to PPV only in aging HIV+ subjects. Continued efforts aimed at improving vaccine responses in this high risk population are warranted.

show abstract

“…Further, this study concluded that circulating IgG had been transferred to the fluid lining the lung. Additionally, IgG did not correlate with CD4 counts (Gordon et al, 2007). These studies imply greater protection conferred by the conjugate vaccine.…”

Section: Chapter Fourmentioning

confidence: 70%

Detection of Subtle Immune Defects in Individuals at Risk of Pneumococcal Disease

Asani¹

2016

Preprint

View full text Add to dashboard Cite

Pneumococcal conjugate vaccine is immunogenic in lung fluid of HIV-infected and immunocompetent adults

Cited by 18 publications

References 10 publications

Advances in basic and clinical immunology in 2007

Advances in basic and clinical immunology in 2007

Quantitative and Functional Antibody Responses to the 13-Valent Conjugate and/or 23-Valent Purified Polysaccharide Vaccine in Aging HIV-Infected Adults

Detection of Subtle Immune Defects in Individuals at Risk of Pneumococcal Disease

Contact Info

Product

Resources

About